drugset / Trial / NCT03236428
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Phase 2
Active not recruiting
42 enrolled
Dana-Farber Cancer Institute
Blood Cancer Research Partnership · collabJanssen Pharmaceuticals · collabMultiple Myeloma Research Consortium · collabThe Leukemia and Lymphoma Society · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
Timeline
- Start
- 2017-11-24
- Primary completion
- 2021-10-04
- Completion
- 2026-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | Intravenous |